


Abstract

The present invention relates to compounds of the formula I



5 and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R¹, R²,
R³, R⁴ and R⁵ are as defined herein. Moreover, the present invention is also
directed at pharmaceutical compositions comprising a compound of the formula I
and a pharmaceutically acceptable carrier. Furthermore, the present invention is
directed at methods of using the herein described compounds and compositions for
10 treating or preventing a disorder or condition that can be treated or prevented by
antagonizing the CCR1 receptor in a mammal.